Samsara BioCapital related stories
All articles and analysis
Rain Therapeutics scores $63m Series BNewark, California-based Rain Therapeutics Inc, a biotechnology company focused on targeted therapies for patients with cancer, has secured $63 million in Series B financing.
Chinook Therapeutics bags $106m in latest financingChinook Therapeutics, a Vancouver, British Columbia-based developer of precision medicines for kidney disease, has raised US$106 million in financing.
VC-backed cell therapy AlloVir goes publicAlloVir Inc, a cell therapy company, has raised $276.25 million for its IPO after pricing its 16.25 million shares at $17 per share.
- Nura Bio reels in $73m Series A
South San Francisco-based Nura Bio Inc, a biopharma company focused on developing neuroprotective drugs, has raised $73 million in Series A funding.
- Unum Therapeutics to raise about $104.4m
Cambridge, Massachusetts-based Unum Therapeutics Inc, a biopharmaceutical company focused on developing therapies for solid tumors, is expected to raise about $104.4 million in a private placement.
- Bolt Biotherapeutics rakes in $93.5m Series C
Redwood City, California-based Bolt Biotherapeutics Inc, a biotechnology company, has raised $93.5 million in Series C financing.
- Autobahn Therapeutics rakes in $76m Series B
San Diego-based Autobahn Therapeutics, a creator of regenerative medicines for people affected by CNS disorders, has raised $76 million in Series B funding.
- VC-backed Chinook Therapeutics to merge with Aduro Biotech
Chinook Therapeutics, a Vancouver-based developer of precision medicines for kidney disease, has agreed to merge with Aduro Biotech.
- Palvella Therapeutics rakes in $45m Series C
Wayne, Pennsylvania-based Palvella Therapeutics Inc., a rare disease biopharmaceutical company, has raised $45 million in Series C financing.
- ElevateBio attracts $170m Series B
Cambridge, Massachusetts-based ElevateBio LLC, a cell and gene therapy company, has secured $170 million in Series B funding.